Please assess the completion status of the following clinical trial:

Trial Title: Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \> 18 years old, diagnosed C diff colitis requiring surgical intervention~Exclusion Criteria:~* CHF previously diagnosed, pregnancy, prisoners/ incarcerated, previous administration of IVIG within 30-days of randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bezlotoxumab (Type: EXPERIMENTAL): Patients receiving Bezlotoxumab post-operatively.
- Normal Saline (Type: PLACEBO_COMPARATOR): Patients receiving normal saline as a placebo post-operatively.

Based on this trial design, predict the completion outcome and termination type (if applicable).